Damage and dysfunction of the myelin plays an essential role in many diseases of the central and peripheral nervous system including hereditary, inflammatory, toxic or infectious disorders. This team of BRIDGE is devoted to the promotion of research exploring destruction and regeneration of myelin across all these disciplines.
In our team, clinicians work together with scientists on projects concerning basic molecular mechanisms of de- and remyelination, discovering and validating biomarkers in multiple sclerosis and neuromyelitis optica spectrum disease, and establishing potential markers of clinical outcome.
We apply in vitro models of glial cell cultures and myelination, and animal models such as cuprizone-induced de/remyelination and experimental autoimmune encephalomyelitis. We conduct a broad spectrum of clinical research involving treatment, management, epidemiology and comorbidity of demyelinating diseases connected to collecting biobank material and structural/functional neuroimaging (MRI and PET).
Through interactive research, extensive national and international collaboration, and organization of symposia, our team in BRIDGE provides a platform for cooperation in the field of demyelinating diseases with the purpose of establishing new interdisciplinary research collaborations with a translational approach.